A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome

Summary

This randomized, double-blind, placebo-controlled, parallel-arm study will evaluate the safety and exploratory efficacy and pharmacokinetics of RO4917523 in pediatric patients with fragile X syndrome. Patients will be randomized to receive one of 2 dose levels of RO4917523 or placebo orally daily for 12 weeks.

Timeline

Start

2013-02

Primary completion

2014-04

Completion

2014-04

Drugs

Indications